Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1Endocrine 1Dermatologic 1CNS 1

Conditions

Sarcoma 2Rhabdomyosarcoma 2Medulloblastoma 2Uveal Melanoma 1Retinoblastoma 1Pituitary Diseases 1Osteosarcoma 1Neuroblastoma 1Mesothelioma 1Melanoma 1Laryngeal Diseases 1Glioma 1Colonic Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1Adenoma, Islet Cell 1

Interventions

Cyclophosphamide 20pembrolizumab 19Nivolumab 10fludarabine 7Radiosurgery 7Specimen Handling 6Ipilimumab 6Injections 5Celecoxib 5poly ICLC 4Radiation 4Paclitaxel 4Melphalan 4Magnetic Resonance Spectroscopy 4Gemcitabine 4Docetaxel 4Cryosurgery 4durvalumab 3cemiplimab 3Filgrastim 3Etoposide 3Cisplatin 3Blood Specimen Collection 3Biopsy 3trastuzumab deruxtecan 2tislelizumab 2talimogene laherparepvec 2spartalizumab 2fludarabine phosphate 2bempegaldesleukin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × LY2940680 × Sarcoma × Clear all
NCT05199584 2026-03-05

A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations

Endeavor Biomedicines, Inc.

Phase 2 Completed
20 enrolled
CNSDermatologicEndocrineHead & NeckOther solid neoplasmSarcomaThoracic

Uveal Melanoma, Glioma, Adenoma, Islet Cell, Laryngeal Diseases, Medulloblastoma, Melanoma, Mesothelioma, Neuroblastoma, Pituitary Diseases, Retinoblastoma, Rhabdomyosarcoma, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡